Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



King's College London - Health: More than a medical matter





Embryonic stem cells used to create insulin-producing cells

26 February 2008

By Dr Charlotte Maden

Appeared in BioNews 446

Scientists in the US have derived insulin-producing cells from human embryonic stem cells (hESCs), and have successfully implanted them into mice. The achievement, reported last week in the journal Nature Biotechnology, could help push forward research into therapies for diabetes.

Type 1 diabetes, and some forms of type 2 diabetes, are caused by a deficiency of pancreatic beta cells. These are cells that produce insulin, the hormone that helps control blood glucose levels, and are part of clusters of hormone-producing cells in the pancreas called the islets of Langerhans. The disease is characterised by a lack of insulin and subsequent misregulation of blood glucose, a condition that can be fatal. Diabetes is currently the seventh leading cause of death in the US, with 200,000 deaths reported per year.

The scientists at Novocell Inc. in San Diego, led by Dr Emmanuel E. Baetge, the chief scientific officer, derived immature precursor pancreatic beta cells from hESCs. They then implanted them into mice whose own beta cells had been destroyed by chemical treatment. After 90 days, the mice had switched the precursor cells into mature beta cells that produced insulin again, which helped control blood glucose. The implanted cells were said to be 'functionally and morphologically similar' to normal beta cells.

Transplanting human islet cells into diabetic patients from donated pancreases has been proven to help treat the symptoms of diabetes, but this technique relies upon donations, of which there is not a consistent supply. There is also a risk of transplanting infected or contaminated cells. The new technology could provide a readily available and renewable bank of clean cells for treatment when the patient needed it.

The scientists say that there is a long way to go before this can be taken into humans. There are safety issues still apparent as some of the mice in the study developed tumours, called 'teratomas'. Some critics are also concerned with whether the transplanted hESC derived cells would be destroyed by the recipient's body, just as their own original beta cells were.

Experts, however, are in no doubt that this is an exciting advancement. 'This for the first time validates that you can use human embryonic stem cells to produce fully functional human islets', says Dr Baetge.

 

SOURCES & REFERENCES
Reuters | 21 February 2008
 
The Washington Post | 20 February 2008
 
ABC News | 20 February 2008
 
Medical News Today | 21 February 2008
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

20 April 2009 - by Rose Palmer 
A pioneering stem cell transplant has enabled patients with Type One diabetes to go without insulin injections for up to four years. Researchers from Northwestern University in the US and the Regional Blood Centre in Brazil treated a total of 23 patients and found that the majority... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to Login or Register to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
RISK ASSESSMENT:
BREAST CANCER, PREDICTION AND SCREENING
FREE public event in central London, 6.30pm on Thursday 8 May 2014 - find out more HERE

ANNIVERSARY APPEAL
Please donate HERE, so that the Progress Educational Trust can continue throughout 2014 (and beyond) while keeping BioNews FREE for you to read

The Progress Educational Trust was shortlisted for the Charity Times Awards 2011

Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation